Fragile promise of psychedelics in psychiatry

Cédric Lemarchand,Raphaël Chopin,Morgane Paul,Alain Braillon,Lisa Cosgrove,Ioana Cristea,Eiko I Fried,Erick H Turner,Florian Naudet
DOI: https://doi.org/10.1136/bmj-2024-080391
2024-11-27
BMJ
Abstract:The US clinical market for ketamine, estimated at $3.1bn in 2022 and expected to expand at 10.6% a year until 2030,1 is just one of many signs of renewed interest in the use of psychedelics to treat psychiatric conditions.2 Various mind altering drugs have already entered the market, including esketamine nasal spray, which the US Food and Drug Administration approved in 2019. And in 2022 the Australian Therapeutic Goods Administration (TGA) allowed psilocybin and 3,4-methylenedioxymethamphetamine (MDMA) to be prescribed by authorised physicians for psychiatric conditions such as depression and post-traumatic stress disorder. The decision was taken despite an independent scientific report commissioned by the TGA advising against authorisation because the certainty of evidence for benefits was low or very low.3Psychedelics, the lay term for substances classified as hallucinogens, have various targets and distinct purported mechanisms of action. For instance, psilocybin is a serotoninergic agonist, whereas esketamine is a N-methyl-D-aspartate (NMDA)...
medicine, general & internal
What problem does this paper attempt to address?